FUNDAMENTALS · Fundamentals · CA Healthcare

Organigram Global (OGI) Fundamentals 2026 — Revenue Analysis | SniperIQ

Organigram Global (OGI) is a CA-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of

29M, trading at $0.92 on the NASDAQ. This SniperIQ fundamentals page covers Organigram Global's valuation, profitability (net margin -9.2%), revenue (CAD 186M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
29M
Net Margin-9.2%
Revenue (FY25)CAD 186M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Organigram Global's market cap?

Organigram Global (OGI) has a market capitalization of approximately

29M, trading at $0.92 on the NASDAQ. Market cap moves with the live share price.

What is Organigram Global's P/E ratio?

Organigram Global's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Organigram Global?

Organigram Global runs a net profit margin of -9.2%, a gross margin of -3.1%, and an operating margin of -38.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Organigram Global generate?

Organigram Global reported revenue of CAD 186M for fiscal year 2025, with net income of -CAD 18M and earnings per share (EPS) of -0.14. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Organigram Global pay a dividend?

Organigram Global does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Organigram Global financially healthy?

Organigram Global carries a debt-to-equity ratio of 0.02x and a current ratio of 2.82x, with a market beta of 1.85. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Organigram Global a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Organigram Global (OGI) the key facts are: market cap

29M, revenue CAD 186M, 52-week range 0.853-2.24. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Organigram Global's full fundamentals live

Get Organigram Global's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Vor Biopharma (VOR) fundamentals · InflaRx (IFRX) fundamentals · Neuronetics (STIM) fundamentals · MaxCyte (MXCT) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons